A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, Yong Zhang et al.|Alzheimer s Research & Therapy|2021Cited by 818
η-Secretase processing of APP inhibits neuronal activity in the hippocampusMichael Willem, Christian Haass, Camilla Giudici et al.|Nature|2015Cited by 372
CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s DiseaseBence György, Martin Ingelsson, Camilla Lööv et al.|Molecular Therapy — Nucleic Acids|2018Cited by 189
Neurofilament ELISA validationAxel Petzold, George P. Paraskevas, Ayşe Altıntaş et al.|Journal of Immunological Methods|2009Cited by 105
Lack of association between schizophrenia and alleles of the dopamine D1, D2, D3 and D4 receptor loci1Markus M. Nöthen, Brian F. O’Dowd, Judith Körner et al.|Psychiatric Genetics|1993Cited by 43